TB-500: Benefits, Handling, the BPC-157 Stack, and Quality Standards
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
TB-500 and BPC-157 are both classified under the World Anti-Doping Agency’s Prohibited List (Sections S0/S2), at all times, for tested athletes.
What is TB-500?
TB-500 is a synthetic peptide fragment corresponding to the actin-binding region of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein present in nearly all human and animal cells. Tβ4 plays a central role in regulating actin, the structural protein cells use to migrate and rebuild tissue. TB-500 reproduces the active region of that protein in a smaller, more stable synthetic form; it does not occur in this isolated fragment naturally.
Benefits and Uses
Available research on Tβ4 and TB-500 spans several areas of interest, with an important distinction: the majority of the published evidence concerns full-length Tβ4 in preclinical and animal models, while direct human evidence for the TB-500 fragment specifically remains sparse:
- Tissue and wound repair. The most extensively studied effect. Full-length Tβ4 has been shown to accelerate reepithelialization and wound contraction in animal wound models, with increased collagen deposition and angiogenesis observed in treated wounds.
- Angiogenesis. Research has examined Tβ4’s role in promoting new blood vessel formation into healing tissue, a process relevant to how well-supplied a repairing tissue becomes.
- Cell migration and actin regulation. Tβ4 is studied for its role in actin sequestration, the mechanism underlying its effect on cell motility toward sites of tissue damage.
- Inflammation modulation. Research has reported anti-inflammatory activity associated with Tβ4 in various tissue contexts.
A 2026 scoping review of the thymosin beta-4/TB-500 literature found the evidence concentrated in ocular and dermal wound-healing settings, with direct evidence for the TB-500 fragment itself limited to a single included study — the broader literature remains largely preclinical, with limited human evidence directly applicable to musculoskeletal research use.
How It Works
Tβ4 works primarily by sequestering G-actin monomers and regulating the actin cytoskeleton, the mechanism believed to drive its effect on cell migration toward injury sites. Research also associates it with upregulation of angiogenic signaling and modulation of inflammatory pathways. The combined picture from animal studies is a coordinated repair process — vascular support, cell migration, and reduced inflammatory signaling — rather than a single isolated mechanism.
Dosage and Administration
No standardized dosing protocol exists for TB-500 outside of individual study designs, and any research protocol, route, or dose is determined solely by the licensed researcher or practitioner and their institution.
Animal and preclinical research has most commonly used intraperitoneal or subcutaneous administration. This reflects historical study design, not a recommended or current protocol.
For labs converting a professional’s own determined research dose into an accurate reconstitution volume, CellGenic’s calculator tool is open to any visitor, with no account required.
Side Effects and Safety
Animal studies have generally reported a favorable tolerability profile for Tβ4. Direct long-term human safety data specific to the TB-500 fragment does not exist in the published literature, and researchers should establish baseline laboratory values before and during any protocol.
The BPC-157 Stack
TB-500 and
BPC-157 are the most frequently studied research pairing in soft-tissue and recovery-related literature. The two peptides are studied through different mechanisms that researchers view as complementary: BPC-157 has been studied for angiogenic and cytoprotective effects concentrated at the site of tissue injury — supported by a body of published research on tendon, ligament, and gastrointestinal tissue models — while
TB-500 is studied for systemic cell migration and broader actin-mediated tissue remodeling.
CellGenic supplies BPC-157 as a standalone research vial, and the combined pairing across three formats:
Quality & Verification Standards
Every CellGenic lot is manufactured under cGMP conditions and undergoes mycoplasma, sterility, identity, and potency testing prior to release. Certificates of Analysis are issued per batch and can be retrieved directly using your batch number.
TB-500 and BPC-157 in CellGenic's Protocols
Within CellGenic’s own provider protocols,
BPC-157 and TB-500 are paired with
GHK-Cu for acute soft-tissue cases — sprains, tears, and back-or-shoulder presentations — and separately layered with GHK-Cu and
DSIP for long-horizon structural repair and inflammatory load reduction, rather than being studied as a two-peptide pair alone. Providers building a recovery-focused protocol can review the full pairings and their component products directly.
Become a Verified Provider
Certificates of Analysis, batch documentation, and pricing are available exclusively to verified physicians, clinic operators, and researchers.
Become a Provider → A CellGenic specialist will follow up within one business day. Once your account is verified, full pricing and Certificates of Analysis unlock automatically.
References:
